Distribution and significance of 14-3-3σ, a novel myeopithelial marker, in normal, benign, and malignant breast tissue

Journal of Pathology

Volumn 202, Issue 3, 2004, Pages 274-285

  Simpson, Peter T ^a   Gale, Theodora ^a   Reis Filho, Jorge S ^a,b   Jones, Chris ^a   Parry, Suzanne ^a   Steele, Dawn ^a   Cossu, Antonio ^c   Budroni, Mario ^d   Palmieri, Giuseppe ^e   Lakhani, Sunil R ^a,f  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF SASSARI   (Italy)

^d Azienda USL 1   (Italy)

^e CNR   (Italy)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

14 3 3 ; Breast cancer; Immunohistochemistry; Myoepithelial carcinoma; Myoepithelial cells

Indexed keywords

ANTIBODY; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN 14 3 3; PROTEIN 14 3 3 SIGMA; PROTEIN P53; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTICLE; BREAST ADENOMA; BREAST DISEASE; BREAST FIBROADENOMA; BREAST HYPERPLASIA; BREAST PAPILLOMA; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CARCINOMA IN SITU; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYSTOSARCOMA PHYLLOIDES; CYTOPLASM; DNA MICROARRAY; ENDOTHELIUM CELL; EPITHELIUM CELL; FIBROCYSTIC BREAST DISEASE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MYOEPITHELIOMA; MYOEPITHELIUM CELL; NERVE CELL; PERICYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; STATISTICAL SIGNIFICANCE; STROMA CELL; TISSUE SECTION; TUMOR SUPPRESSOR GENE;

BREAST DISEASES; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL NUCLEUS; CHI-SQUARE DISTRIBUTION; CYTOPLASM; EXONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MYOEPITHELIOMA; NEOPLASM PROTEINS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 12144291537     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1530     Document Type: Article

References (55)

1. Yaziji H, Gown AM, Sneige N. Detection of stromal invasion in breast cancer: the myoepithelial markers. Adv Anat Pathol 2000; 7: 100-109.
2. Joshi MG, Lee AK, Pedersen CA, Schnitt S, Camus MG, Hughes KS. The role of immunocytochemical markers in the differential diagnosis of proliferative and neoplastic lesions of the breast. Mod Pathol 1996; 9: 57-62.
3. Reis-Filho JS, Schmitt FC. Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol 2002; 9: 280-289.
4. Lakhani SR, O'Hare MJ. The mammary myoepithelial cell - Cinderella or ugly sister? Breast Cancer Res 2001; 3: 1-4.
5. Moritani S, Kushima R, Sugihara H, Bamba M, Kobayashi TK, Hattori T. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol 2002; 15: 397-405.
6. Barbareschi M, Pecciarini L, Cangi MG, et al p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001; 25: 1054-1060.
7. Werling RW, Hwang H, Yaziji H, Gown AM. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol 2003; 27: 82-90.
8. Heatley M, Maxwell P, Whiteside C, Toner P. Cytokeratin intermediate filament expression in benign and malignant breast disease. J Clin Pathol 1995; 48: 26-32.
9. Otterbach F, Bankfalvi A, Bergner S, Decker T, Krech R, Boecker W. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 2000; 37: 232-240.
10. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002; 15: 6-10.
11. Chu PG, Lyda MH, Weiss LM. Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial tumours. Histopathology 2001; 39: 9-16.
12. Lakhani SR, O'Hare MJ, Monaghan P, Winehouse J, Gazet JC, Sloane JP. Malignant myoepithelioma (myoepithelial carcinoma) of the breast: a detailed cytokeratin study. J Clin Pathol 1995; 48: 164-167.
13. Lele SM, Graves K, Gatalica Z. Immunohistochemical detection of maspin is a useful adjunct in distinguishing radial sclerosing lesion from tubular carcinoma of the breast. Appl Immunohistochem Mol Morphol 2000; 8: 32-36.
14. Foschini MP, Scarpellini F, Gown AM, Eusebi V. Differential expression of myoepithelial markers in salivary, sweat and mammary glands. Int J Surg Pathol 2000; 8: 29-37.
15. Reis-Filho JS, Milanezi F, Silva P, Schmitt FC. Maspin expression in myoepithelial tumours of the breast. Pathol Res Pract 2001; 197: 817-821.
16. Yang A, Schweitzer R, Sun D, et al p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714-718.
17. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398: 708-713.
18. Page MJ, Amess B, Townsend RR, et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci U S A 1999; 96: 12 589-12 594.
19. Clarke C, Titley J, Davies S, O'Hare MJ. An immunomagnetic separation method using superparamagnetic (MACS) beads for large-scale purification of human mammary luminal and myoepithelial cells. Epithelial Cell Biol 1994; 3: 38-46.
20. van Hemert MJ, Steensma HY, van Heusden GP. 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays 2001; 23: 936-946.
21. Tzivion G, Shen YH, Zhu J. 14-3-3 proteins; bringing new definitions to scaffolding. Oncogene 2001; 20: 6331-6338.
22. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11.
23. Laronga C, Yang HY, Neal C, Lee MH. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 2000; 275: 23 106-23 112.
24. Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A 2000; 97: 6049-6054.
25. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401: 616-620.
26. Prasad GL, Valverius EM, McDuffie E, Cooper HL. Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ 1992; 3: 507-513.
27. Dellambra E, Golisano O, Bondanza S, et al. Downregulation of 14-3-3 sigma prevents clonal evolution and leads to immortalization of primary human keratinocytes. J Cell Biol 2000; 149: 1117-1130.
28. Iwata N, Yamamoto H, Sasaki S, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 2000; 19: 5298-5302.
29. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genet 2002; 31: 141-149.
30. Osada H, Tatematsu Y, Yatabe Y, et al. Frequent and histological type-specific inactivation of 14-3-3 sigma in human lung cancers. Oncogene 2002; 21: 2418-2424.
31. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001; 20: 3348-3353.
32. Yatabe Y, Osada H, Tatematsu Y, Mitsudomi T, Takahashi T. Decreased expression of 14-3-3 sigma in neuroendocrine tumours is independent of origin and malignant potential. Oncogene 2002; 21: 8310-8319.
33. Nakajima T, Shimooka H, Weixa P, et al. Immunohistochemical demonstration of 14-3-3 sigma protein in normal human tissues and lung cancers, and the preponderance of its strong expression in epithelia] cells of squamous cell lineage. Pathol Int 2003; 53: 353-360.
34. Jones C, Nonni AV, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 2001; 85: 422-427.
35. Jones C, Foschini MP, Chaggar R, et al. Comparative genomic hybridization analysis of myoepithelial carcinoma of the breast. Lab Invest 2000; 80: 831-836.
36. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nature Med 1998; 4: 844-847.
37. Mackay A, Jones C, Dexter T, et al cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 2003; 22: 2680-2688.
38. Gobbi H, Dupont WD, Simpson JF, et al. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 1999; 91: 2096-2101.
39. Boecker W, Moll R, Dervan P, et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 2002; 198: 458-467.
40. Reis-Filho JS, Milanezi F, Paredes J, et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol 2003; 11: 1-8.
41. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, et al. Proteomic analysis reveals that 14-3-3 sigma is down-regulated in human breast cancer cells. Cancer Res 2001; 61: 76-80.
42. Taylor-Papadimitriou J, Lane EB. Keratin expression in the mammary gland. In The Mammary Gland: Development, Regulation and Function, Neville MC, Daniel CW (eds). Plenum: New York, 1987; 181-215.
43. Nacht M, Ferguson AT, Zhang W, et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999; 59: 5464-5470.
44. O'Hare MJ, Ormerod MG, Monaghan P, Lane EB, Gusterson BA. Characterization in vitro of luminal and myoepithelial cells isolated from the human mammary gland by cell sorting. Differentiation 1991; 46: 209-221.
45. DiRenzo J, Signoretti S, Nakamura N, et al. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res 2002; 62: 89-98.
46. Tsuda H, Takarabe T, Hasegawa T, Murata T, Hirohashi S. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol 1999; 30: 1134-1139.
47. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large, central acellular zones indicating myoepithelial tumour differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000; 24: 197-202.
48. Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003; 12: 27-34.
49. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
50. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10 869-10 874.
51. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161: 1991-1996.
52. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-8423.
53. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100: 10 393-10 398.
54. Zilliacus J, Holter E, Wakui H, Tazawa H, Treuter E, Gustafsson JA. Regulation of glucocorticoid receptor activity by 14-3-3-dependent intracellular relocalisation of the corepressor RIP140. Mol Endocrinol 2001; 15: 501-511.
55. Kino T, Souvatzoglou E, De Martino MU, Tsopanomihalu M, Wan Y, Chrousos GP. Protein 14-3-3σ interacts with and favors cytoplasmic subcellular localisation of the glucocorticoid receptor, acting as a negative regulator of the glucocorticoid signalling pathway. J Biol Chem 2003; 278: 25 651-25 656.